29th Jul 2010 07:00
AstraZeneca Development Pipeline
29 July 2010
Line Extensions
|
Compound |
Mechanism |
Area Under Investigation |
Phase |
Estimated Filing | |
| MAA | NDA | ||||
| Cardiovascular | |||||
Crestor |
statin |
outcomes in subjects with elevated CRP |
III |
Launched |
Launched |
Dapagliflozin/ metformin FDC# |
SGLT2 inhibitor + metformin FDC |
diabetes |
III |
1H 2012 |
1H 2012 |
|
Onglyza/ metformin FDC# |
DPP-4 inhibitor + metformin FDC |
diabetes |
III |
3Q 2010 |
Filed |
Onglyza# |
DPP-4 inhibitor |
outcomes study |
III |
|
2016 |
|
Gastrointestinal |
|||||
Axanum |
proton pump inhibitor + low dose aspirin FDC |
low dose aspirin associated peptic ulcer |
III |
Filed* |
Filed |
Nexium |
proton pump inhibitor |
peptic ulcer bleeding |
III |
Launched |
Filed |
|
Neuroscience |
|||||
Seroquel XR |
D2/5HT2 antagonist |
major depressive disorder |
III |
Filed |
Launched** |
Seroquel XR |
D2/5HT2 antagonist |
generalised anxiety disorder |
III |
Filed |
Withdrawn |
|
Oncology & Infection |
|||||
Faslodex |
oestrogen receptor antagonist |
first line advanced breast cancer |
III |
|
|
Faslodex |
oestrogen receptor antagonist |
high dose (500mg) second line advanced breast cancer |
III |
Launched |
Filed |
FluMist
|
live, attenuated, intranasal influenza virus vaccine |
influenza |
III |
Filed |
Launched |
Iressa |
EGFR tyrosine kinase inhibitor |
NSCLC |
III |
Launched |
TBD |
|
Motavizumab# |
humanized mAb binding to RSV F protein |
early and late treatment of RSV in paeds >1 yr |
II |
|
2015 |
#Partnered product
*Previously submission was indication only. Now covers fixed dose combination
**Adjunct only, monotherapy withdrawn
Onglyza and dapagliflozin are being co-developed with Bristol-Myers Squibb NCEs
Phase III/Registration
|
Compound |
Mechanism |
Area Under Investigation |
Phase |
Estimated Filing | |
| MAA | NDA | ||||
| Cardiovascular | |||||
Brilinta/Brilique |
ADP receptor antagonist |
arterial thrombosis |
III |
Filed |
Filed |
Certriad# |
statin + fibrate FDC |
dyslipidaemia |
III |
|
Filed |
Dapagliflozin# |
SGLT2 inhibitor |
diabetes |
III |
4Q 2010* |
4Q 2010* |
|
Neuroscience |
|||||
TC-5214# |
nicotinic ion channel blocker |
major depressive disorder (adjunct) |
III |
2014 |
2012 |
Vimovo# |
naproxen + esomeprazole |
signs and symptoms of OA, RA and AS |
III |
Filed |
Approved |
|
Oncology & Infection |
|||||
Ceftaroline# |
extended spectrum cephalosporin with affinity to penicillin- binding proteins |
pneumonia /skin infections |
III |
4Q 2010 |
NA |
MEDI-3250 |
flu vaccine (quadrivalent) |
seasonal influenza |
III |
|
1H 2011 |
Motavizumab# |
humanized MAb binding to RSV F protein |
RSV prevention |
III |
4Q 2010 |
Filed |
|
Vandetanib (Zactima) |
VEGFR/EGFR tyrosine kinase inhibitor with RET kinase activity |
medullary thyroid cancer - orphan |
III |
3Q 2010 |
3Q 2010 |
Zibotentan (ZD4054) |
endothelin A receptor antagonist |
castrate resistant prostate cancer |
III |
1H 2011 |
1H 2011 |
#Partnered product
\* Timing subject to CV event rate
NCEs
Phases I and II
Compound |
Mechanism |
Area Under Investigation |
Phase | Estimated Filing | |
| MAA | NDA | ||||
| Cardiovascular | |||||
AZD1656 |
GK activator |
diabetes |
II |
2015 |
2015 |
AZD6370 |
GK activator |
diabetes |
II |
|
|
AZD4017 |
11BHSD inhibitor |
diabetes/obesity |
I |
|
|
AZD6714 |
GK activator |
diabetes |
I |
|
|
AZD7687 |
diacylglycerol acyl transferase -1 inhibitor |
diabetes/obesity |
I |
|
|
AZD8329 |
11BHSD inhibitor |
diabetes/obesity |
I |
|
|
|
Gastrointestinal |
|||||
AZD1386 |
vanilloid receptor antagonist |
GERD |
II |
|
|
Lesogaberan (AZD3355) |
GABAB agonist |
GERD |
II |
2013 |
2013 |
AZD2066 |
metabotropic glutamate receptor 5 antagonist |
GERD |
I |
|
|
AZD2516 |
metabotropic glutamate receptor 5 antagonist |
GERD |
I |
|
|
NCEs
Phases I and II (continued)
|
Compound |
Mechanism |
Area Under Investigation |
Phase |
Estimated Filing | |||||
| MAA | NDA | ||||||||
|
Neuroscience |
|||||||||
AZD1446# |
Alpha4/beta2 neuronal nicotinic receptor agonist |
Alzheimer's disease/ADHD |
II |
|
|
||||
AZD2066 |
metabotropic glutamate receptor 5 antagonist |
chronic neuropathic pain |
II |
|
|
||||
AZD2066 |
metabotropic glutamate receptor 5 antagonist |
major depressive disorder |
II |
|
|
||||
AZD2327 |
enkephalinergic receptor modulator |
depression/anxiety |
II |
|
|
||||
AZD3480# |
Alpha4/beta2 neuronal nicotinic receptor agonist |
ADHD |
II |
|
|
||||
AZD6765 |
NMDA receptor antagonist |
major depressive disorder |
II |
2015 |
2014 |
||||
AZD7268 |
enkephalinergic receptor modulator |
depression/anxiety |
II |
|
|
||||
AZD8529 |
glutamatergic modulator |
schizophrenia |
II |
|
|
||||
NKTR-118# |
oral peripherally-acting opioid antagonist |
opioid-induced constipation |
II |
2013 |
2013 |
||||
TC-5214# |
nicotinic ion channel blocker |
major depressive disorder (monotherapy) |
II |
|
|
||||
TC-5619# |
Alpha7 neuronal nicotinic receptor agonist |
cognitive disorders in schizophrenia |
II |
|
|
||||
AZD2423 |
chemokine antagonist |
chronic neuropathic pain |
I |
|
|
||||
AZD2516 |
metabotropic glutamate receptor 5 antagonist |
chronic neuropathic pain |
I |
|
|
||||
AZD3043# |
GABA-A receptor modulator |
short acting sedative/anaesthetic |
I |
|
|
||||
AZD3241 |
myeloperoxidase (MPO) inhibitor |
Parkinson's disease |
I |
|
|
||||
AZD5213 |
H3AN |
Alzheimer's disease/ADHD |
I |
|
|
||||
MEDI-578 |
anti-NGF mAb |
OA pain |
I |
|
|
||||
#Partnered product
NCEs
Phases I and II (continued)
|
Compound |
Mechanism |
Area Under Investigation |
Phase |
Estimated Filing | |
| MAA | NDA | ||||
|
Oncology & Infection |
|||||
Recentin |
VEGFR tyrosine kinase inhibitor |
NSCLC |
II |
2013 |
2013 |
AZD9773 (CytoFab)# |
anti-TNF-alpha polyclonal antibody |
severe sepsis |
II |
2015 |
2015 |
AZD6244#(ARRY-142886) |
MEK inhibitor |
solid tumours |
II |
2014 |
2014 |
|
Olaparib
|
PARP inhibitor |
gBRCA breast cancer |
II |
2014 |
2014 |
Olaparib |
PARP inhibitor |
serous ovarian cancer |
II |
2014 |
2014 |
|
AZD7295 |
NS 5A inhibitor |
hepatitis C |
II |
2015 |
2015 |
|
AZD1152 |
aurora kinase inhibitor |
haematological malignancies |
II |
2014 |
2014 |
|
CAZ104# |
beta lactamase inhibitor/cephalosporin |
serious infections |
II |
2012 |
NA |
|
AZD8931 |
erbB kinase inhibitor |
solid tumours |
II |
2015 |
2015 |
|
AZD4769 |
EGFR tyrosine kinase inhibitor |
solid tumours |
I |
|
|
|
AZD7762 |
Chk1 kinase inhibitor |
solid tumours |
I |
|
|
|
AZD8330# (ARRY-424704) |
MEK inhibitor |
solid tumours |
I |
|
|
|
CAT-8015 |
anti-CD22 recombinant immunotoxin |
haematological malignancies |
I |
|
|
|
MEDI-534
|
RSV/PIV-3 vaccine |
RSV/PIV prophylaxis |
I |
|
|
|
MEDI-551 |
CD19 |
haematological malignancies |
I |
|
|
|
MEDI-560
|
PIV-3 vaccine |
PIV prophylaxis |
I |
|
|
|
MEDI-550 |
pandemic influenza virus vaccine |
pandemic influenza prophylaxis |
I |
|
|
|
MEDI-557
|
RSV mAb - extended half-life |
COPD |
I |
|
|
|
AZD8055 |
TOR kinase inhibitor |
range of tumours |
I |
|
|
|
MEDI-559 |
RSV vaccine |
RSV prophylaxis |
I |
|
|
|
MEDI-573 |
IGF |
solid tumours |
I |
|
|
|
MEDI-575 |
PDGFR-alpha |
solid tumours |
I |
|
|
|
AZD1480 |
JAK2 inhibitor |
myeloproliferative diseases/solid tumours |
I |
|
|
|
AZD5847 |
Oxazolidinone antibacterial inhibitor |
tuberculosis |
I |
|
|
|
AZD4547 |
FGFR tyrosine kinase inhibitor |
solid tumours |
I |
|
|
|
MEDI-547# |
EphA2 conjugate |
solid tumours |
I |
|
|
|
AZD9742 |
BTGT4 IV |
MRSA |
I |
|
|
|
CEF104# |
beta lactamase inhibitor/cephalosporin |
MRSA |
I |
|
|
|
AZD2014 |
TOR kinase inhibitor |
solid tumours |
I |
|
|
|
AZD6244 (ARRY-142886) /MK2206# |
MEK/AKT inhibitor |
solid tumours |
I |
|
|
Phases I and II (continued)
|
Compound |
Mechanism |
Area Under Investigation |
Phase |
Estimated Filing | |
| MAA | NDA | ||||
|
Respiratory & Inflammation |
|||||
AZD1981 |
CRTh2 receptor antagonist |
asthma/COPD |
II |
|
|
|
AZD3199 |
iLABA |
asthma/COPD |
II |
|
|
AZD8848 |
Toll like receptor 7 agonist |
asthma |
II |
|
|
|
AZD9668 |
neutrophil elastase inhibitor |
COPD |
II |
2014 |
2014 |
CAM-3001# |
anti-GM-CSFR mAb |
rheumatoid arthritis |
II |
|
|
|
CAT-354 |
anti-IL-13 mAb |
asthma |
II |
|
|
MEDI-528# |
anti-IL-9 mAb |
asthma |
II |
|
|
|
MEDI-545# |
anti-IFN-alpha mAb |
SLE, myositis |
II |
|
|
|
MEDI-563# |
anti-IL-5R mAb |
asthma |
II |
|
|
Fostamatinib Disodium# |
spleen tyrosine kinase (syk) inhibitor |
rheumatoid arthritis |
II |
2013 |
2013 |
AZD5069 |
CXCR2 |
COPD |
I |
|
|
AZD5423 |
iSEGRA |
COPD |
I |
|
|
AZD6553 |
neutrophil elastase inhibitor |
COPD |
I |
|
|
AZD8683 |
muscarinic antagonist |
COPD |
I |
|
|
MEDI-546# |
anti-IFNalphaR mAb |
scleroderma |
I |
|
|
MEDI-551 |
anti-CD19 mAb |
scleroderma |
I |
|
|
MEDI-570# |
anti-ICOS mAb |
SLE |
I |
|
|
#Partnered product
AstraZeneca Development Pipeline
Discontinued Projects vs 28 Jan 2010 FY
Cardiovascular/Gastrointestinal
|
NCE/Line Extension |
Compound |
Area Under Investigation |
|
NCE |
AZD0837 |
thrombosis |
|
NCE |
AZD6482 |
thrombosis |
Neuroscience
|
NCE/Line Extension |
Compound |
Area Under Investigation |
|
NCE |
AZD6280 |
anxiety |
|
NCE |
AZD8418 |
schizophrenia |
Oncology & Infection
|
NCE/Line Extension |
Compound |
Area Under Investigation |
|
NCE |
RECENTIN |
CRC |
|
NCE |
RECENTIN |
recurrent glioblastoma |
Respiratory & Inflammation
|
NCE/Line Extension |
Compound |
Area Under Investigation |
|
NCE |
AZD1236 |
COPD |
|
NCE |
AZD2551 |
COPD |
|
NCE |
AZD5122 |
COPD |
|
NCE |
AZD5985 |
asthma/COPD |
|
NCE |
AZD8075 |
asthma/COPD |
|
NCE |
AZD8566 |
COPD |
|
NCE |
AZD9164 |
COPD |
Comments
As disclosure of compound information is balanced by the business need to maintain confidentiality, information in relation to some compounds listed here has not been disclosed at this time.
Compounds in development are displayed by phase.
Key:
MAA - Marketing Authorisation Application (Europe).
NDA - New Drug Application/Biologics Licensing Application (USA).
Related Shares:
Astrazeneca